Septerna, Inc. (NASDAQ:SEPN) Director Purchases $248,130.00 in Stock

Septerna, Inc. (NASDAQ:SEPN) Director Alan Ezekowitz purchased 41,355 shares of the stock in a transaction on Thursday, March 6th. The shares were purchased at an average price of $6.00 per share, with a total value of $248,130.00. Following the acquisition, the director now directly owns 104,101 shares in the company, valued at $624,606. This represents a 65.91 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Alan Ezekowitz also recently made the following trade(s):

• On Tuesday, March 4th, Alan Ezekowitz purchased 7,491 shares of Septerna stock. The shares were purchased at an average price of $6.35 per share, with a total value of $47,567.85.

Septerna Stock Up 1.1 %

Shares of Septerna stock opened at $6.43 on Friday. The firm has a fifty day moving average of $14.10. Septerna, Inc. has a 12-month low of $4.17 and a 12-month high of $28.99.

Analysts Set New Price Targets

SEPN has been the subject of several research analyst reports. TD Cowen initiated coverage on shares of Septerna in a report on Tuesday, November 19th. They issued a “buy” rating for the company. JPMorgan Chase & Co. initiated coverage on shares of Septerna in a report on Tuesday, November 19th. They issued an “overweight” rating and a $38.00 target price for the company. Wells Fargo & Company cut shares of Septerna from an “overweight” rating to an “equal weight” rating and lowered their target price for the company from $43.00 to $14.00 in a report on Tuesday, February 18th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $50.00 target price on shares of Septerna in a report on Tuesday, February 11th.

Institutional Trading of Septerna

A number of large investors have recently bought and sold shares of SEPN. SG Americas Securities LLC acquired a new stake in Septerna during the 4th quarter worth $185,000. Rhumbline Advisers acquired a new stake in Septerna during the 4th quarter worth $458,000. New York State Common Retirement Fund acquired a new stake in Septerna during the 4th quarter worth $32,000. Bank of New York Mellon Corp acquired a new stake in Septerna during the 4th quarter worth $872,000. Finally, Charles Schwab Investment Management Inc. acquired a new stake in Septerna during the 4th quarter worth $3,197,000.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.